Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
about
sameAs
Risperidone versus other atypical antipsychotics for schizophreniaClozapine versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaReview of depot aripiprazole for schizophreniaLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsDevelopment of and recovery from difficulty with activities of daily living: an analysis of national data.Predictors of switching antipsychotic medications in the treatment of schizophreniaChange in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychoticsPrescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009.Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational studyTreatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence.Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entryTwo-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study.Effectiveness of sulpiride in adult patients with schizophrenia.Are second generation antipsychotics a distinct class?Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive DisorderCost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Effectiveness studies: advantages and disadvantages.Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom.Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in JapanEstimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders.The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders.Pd-Catalyzed double N-arylation of primary amines to synthesize phenoxazines and phenothiazines.Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review.
P2860
Q24234950-F6457208-DF0F-4A01-AE04-9E738D339B6AQ24236422-B5AA32A7-59C9-4A40-B583-271A8ED7E348Q24236545-4361D24F-9503-4CF4-B552-C4CFA23D9127Q24240260-D4C25EC3-185A-47B2-A074-A0757FE35039Q24240989-D9914E70-B4C4-41F7-A022-55DCE390EEF4Q27008464-8A11FCF5-4A16-4C41-8273-54EB2F3BACA5Q28085407-8843C41F-ECD5-404E-820D-0A9D0C24A718Q33641065-021DDE71-6ED9-423E-9989-AEDE6D4CC3F6Q33709704-8A048399-E74A-4917-AEFF-8A1B4906CAB2Q33903511-1436C3DA-8D56-4F78-9F75-25CCB53BD65FQ34098311-5808BED4-CB74-4910-83CF-F1119FD0B196Q34318836-E025A73E-EE24-4E9D-BFDE-76A79F44B374Q34502693-08ECD8D3-43D7-4725-8C35-2DD9F1E12180Q35018988-D388574C-6E6A-461F-BE55-799C8AD93AD0Q35568945-FC63EC21-9A28-44C7-8824-0CB507E7D3E8Q35851083-4712C4EA-FA0B-4456-9974-CE3E601349F4Q36609365-CFF6B9CC-157B-4A0B-AC15-BA9F2C10FEA4Q36770037-2753F15B-0078-41B5-87CB-C05E686A25F5Q36784527-2F6BDADC-D09C-438A-A4F6-5225041C308BQ37052769-F709823E-528A-4866-A1D9-EFB60E90EE60Q37136995-12E075EC-6C24-48E6-B654-642AC7D62DC9Q37185914-1F7A2476-3D56-42DA-BF4B-E30677DB5750Q37405519-55B0EC3A-4E8F-4EBC-ABC1-4F8FCDFAA2A5Q37917728-79CD829D-D545-47CE-BDB5-891880D889E4Q37985887-4B6E7FA8-168B-483E-9351-96AD0515CB97Q38244017-2DA1E2A2-8C02-4468-93A7-16E7CF6AF9ACQ38437417-83A161B4-9A9B-4FC1-B459-7C58F9535CE9Q40427460-1A4B7826-3939-47A0-9F20-0890426406F4Q40501293-36D8BD7C-8BA2-42D6-BD0D-6B1644FC79AAQ41449760-5C1EC8F9-1E27-44F3-BCB9-B7E2CBFF62AAQ42264057-D3028DA4-8595-4A0C-A8C7-6CE5C4527A89Q43228765-DF1C0AEB-035F-40AD-AAC2-3048B6BE164BQ44243570-B0DFB794-F067-4073-87A7-6A733C13E9D7Q44673143-1D87BA97-C1FD-47C0-86C9-838D43B43E01Q47785684-E4AED0B1-6C7C-44E3-8439-68CA44B60DBDQ47915791-56B6CD65-73C8-4C1C-AE0F-68046D7EC2D6Q52579281-66CB9EE7-0D2B-42CE-8AF8-19086A36155E
P2860
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Time to discontinuation of aty ...... tic treatment of schizophrenia
@ast
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en-gb
Time to discontinuation of aty ...... tic treatment of schizophrenia
@nl
type
label
Time to discontinuation of aty ...... tic treatment of schizophrenia
@ast
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en-gb
Time to discontinuation of aty ...... tic treatment of schizophrenia
@nl
prefLabel
Time to discontinuation of aty ...... tic treatment of schizophrenia
@ast
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en-gb
Time to discontinuation of aty ...... tic treatment of schizophrenia
@nl
P2093
P2860
P3181
P356
P1433
P1476
Time to discontinuation of aty ...... tic treatment of schizophrenia
@en
P2093
Baojin Zhu
Douglas Faries
Jeff Swanson
Marvin Swartz
Ron Landbloom
P2860
P2888
P3181
P356
10.1186/1471-244X-6-8
P407
P577
2006-02-21T00:00:00Z
P6179
1008909132